Clinical Trial Update: A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) [Phase 3]

View source ↗

Summary

A Phase 3 trial (MK-6482-011) compares belzutifan in combination with lenvatinib versus cabozantinib for renal cell carcinoma; the study is active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Belzutifan (belzutifan)
• Lenvatinib (lenvatinib)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING